{"id":42676,"date":"2015-05-13T00:00:00","date_gmt":"2015-05-12T22:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/actualidad-inversion-biotecnologia-era-biotech-aura-bioscience-quirumed-otras-marzo-2015\/"},"modified":"2025-03-12T11:34:27","modified_gmt":"2025-03-12T10:34:27","slug":"actualidad-inversion-biotecnologia-era-biotech-aura-bioscience-quirumed-otras-marzo-2015","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/actualidad-inversion-biotecnologia-era-biotech-aura-bioscience-quirumed-otras-marzo-2015\/","title":{"rendered":"Biotech investment news: Era Biotech, Aura Bioscience, Quirumed and others (March 2015)"},"content":{"rendered":"
In March 2015, the biotechnology sector in Spain has been the protagonist of several investment operations, both venture capital and private equity. mergers and acquisitions<\/a> of companies.<\/span><\/address>\n

<\/span><\/p>\n

 <\/p>\n

 <\/p>\n

Venture capital invests in biotech: Inveready, Ysios<\/strong><\/span><\/p>\n

Venture capital investment in biotechnology worldwide has grown considerably in 2014. In the US, biotech has become the second most preferred sector for venture capital after software, growing by 29% in 2014.<\/span><\/p>\n

In Spain, several operations were also carried out in March. Inveready<\/a> has taken over the assets of Era Biotech<\/a>Era Biotech was founded in 2002 and specialised in innovative solutions in vaccines and molecules. Inveready has committed before the commercial judge to take on a team of four professionals, led by Miriam Bastida -one of the company's founders-, and to invest 1.5 million euros in the firm over a period of six years.<\/span><\/p>\n

\"Inveready is betting on biotechnology, in May 2015 the CDTI has injected \u20ac5M into the Inveready Innvierte Biotech II fund, which aims to invest in\u00a0<\/strong>early stage companies that require between 1 and 4 M of investment and whose developments are related to the creation of new drugs, diagnostics and prognostics, and nutraceutical and functional products\" says Diego Gutierrez of Abra- Invest<\/a>.<\/span><\/p>\n

Ysios Capital<\/a> has entered the US Aura Biosciences<\/a> through an \u20ac18.8M funding round, in which also participated Chiesi Ventures<\/a>, Alexandria Venture Investments<\/a>as well as the company's existing partners: Li-Cor Biosciences <\/a>and Henri Termeer, former CEO of Genzyme.<\/span><\/p>\n

\"This investment is the second by Ysios BioFund II, which two weeks before announcing this round had invested in Switzerland's Prexton Therapeutics. Both are signs of the international orientation of Ysios' investments,\" says Diego Gutierrez.<\/span><\/p>\n

Acquisitions in the sector<\/strong><\/span><\/p>\n

Grifols<\/a> buys US-based Alkahest's 45% for \u20ac33.3M. Alkahest is a company created in 2014 to advance research conducted by a group of Stanford University scientists who pioneered the idea that a component of the blood of young animals has the ability to restore cognitive abilities in old animals. Alkahest is currently conducting research to see if this model could be transferred to humans.<\/span><\/p>\n

Suara<\/a>has started its international expansion with the acquisition of Serproen Home Care<\/a>Suara is a Chilean company specialising in home health care. Suara is a Catalan cooperative that offers a range of services, including care homes for the elderly and nursery schools.<\/span><\/p>\n

With the aim of providing comprehensive care, Suara will complement its activities with home care for dependents and the construction of retirement homes and day centres.\u00a0<\/span><\/p>\n

 <\/p>\n

If you are looking for financing, we can help you, please contact us on +34 946424142.<\/span><\/p>\n

\u00a0Other posts that may interest you<\/span><\/strong><\/p>\n

Sendabio with the help of Abra Invest closes investment round<\/a><\/p>\n

Operations Biotechnology February 2015<\/a><\/p>","protected":false},"excerpt":{"rendered":"

En Marzo de 2015 el sector biotecnol\u00f3gico en Espa\u00f1a ha sido protagonista de varias operaciones de inversi\u00f3n, tanto de capital riesgo como de fusiones y adquisiciones de empresas.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1750],"tags":[238,171],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42676","post","type-post","status-publish","format-standard","hentry","category-financiacion-sectorial","tag-biotecnologia","tag-capital-riesgo","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42676"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42676\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42676"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42676"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}